Zanzalintinib for Advanced Olfactory Neuroblastoma
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This study tests a new targeted drug called zanzalintinib for patients with olfactory neuroblastoma (a rare cancer in the nasal cavity) that has come back or spread. The drug blocks proteins that help tumors grow, and this trial will see if it can help patients who cannot have surgery or radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older with a confirmed diagnosis of recurrent or metastatic olfactory neuroblastoma
- Your cancer cannot be treated with surgery or radiation aimed at curing you
- You have measurable tumors that can be tracked on scans
- You are in good enough health (Eastern Cooperative Oncology Group performance status 0 or 1, meaning you can do most normal activities)
- You have never been treated with VEGFR inhibitors (a class of cancer drugs) before
- Your blood counts, kidney function, and liver function meet specific healthy ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called zanzalintinib for people with advanced or metastatic bone sarcomas that have not responded to standard treatments. It aims to see if the drug can help shrink or slow the growth of these tumors.
This trial is looking at whether a new combination of two drugs, zanzalintinib and pembrolizumab, can help people with certain types of advanced soft-tissue sarcoma that have not responded to other treatments. It aims to find out if the combination is safe and effective.
This trial tests the drug nivolumab for people with a rare nasal tumor (olfactory neuroblastoma) that has come back or spread and cannot be treated with surgery or radiation. You must have already tried chemotherapy and it stopped working. The goal is to see if nivolumab can shrink the tumor or slow its growth.
This trial studies an experimental drug called zanzalintinib for people with adenoid cystic carcinoma that has spread or come back. The goal is to see if the drug can shrink tumors or slow the disease.
This study tests an oral drug called zanzalintinib in children and teens with certain solid tumors that have come back or not responded to treatment. The goal is to see if the drug is safe and works against the cancer.
This trial tests an oral drug called zanzalintinib in people with pheochromocytoma or paraganglioma that has spread or cannot be removed by surgery and has gotten worse. The goal is to see if the drug can slow or stop tumor growth.
Hear when a new Metastatic Olfactory Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.